| Literature DB >> 26242308 |
Takayuki Kawata1, Masao Daimon2, Sakiko Miyazaki3, Ryoko Ichikawa4, Masaki Maruyama5, Shuo-Ju Chiang6, Chiharu Ito7, Fumihiko Sato8, Hirotaka Watada9, Hiroyuki Daida10.
Abstract
BACKGROUND: Left ventricular (LV) diastolic dysfunction is known as an early marker of myocardial alterations in patients with diabetes. Because microvascular disease has been regarded as an important cause of heart failure or diastolic dysfunction in diabetic patients, we tested the hypothesis that coronary flow reserve (CFR), which reflects coronary microvascular function, is associated with LV diastolic dysfunction in patients with type 2 diabetes.Entities:
Mesh:
Year: 2015 PMID: 26242308 PMCID: PMC4525728 DOI: 10.1186/s12933-015-0263-7
Source DB: PubMed Journal: Cardiovasc Diabetol ISSN: 1475-2840 Impact factor: 9.951
Fig. 1Example of Doppler tracing of LAD blood flow during baseline and after adenosine injection (hyperemia).
Fig. 2Patient flow diagram. Of the consecutive 75 patients who were studied, 8 were excluded. Sixty-seven patients were enrolled and completed the entire protocol.
General characteristics of the study population
| Variables | Patients (n = 67) | Controls (n = 14) | p |
|---|---|---|---|
| Age (years) | 57 ± 12 | 56 ± 10 | 0.74 |
| Male (%) | 50 (74) | 9 (64) | 0.31 |
| BMI (kg/m2) | 25.8 ± 4.6 | 24.4 ± 3.7 | 0.24 |
| SBP (mmHg) | 118 ± 17 | 124 ± 12 | 0.13 |
| DBP (mmHg) | 63 ± 12 | 68 ± 7 | 0.075 |
| HR (bpm) | 68 ± 11 | 68 ± 8 | 0.94 |
| RPP | 8034 ± 1713 | 8558 ± 1233 | 0.26 |
| Hypertension (%) | 38 (57) | 9 (64) | 0.42 |
| Dyslipidemia (%) | 34 (51) | 8 (57) | 0.44 |
| Diabetes treatment | |||
| Diet (%) | 10 (15) | – | |
| Sulfonylurea (%) | 11 (16) | – | |
| Glinide (%) | 9 (13) | – | |
| Biguanide (%) | 22 (33) | – | |
| Thiazolidinedione (%) | 9 (13) | – | |
| α-glucosidase inhibitor (%) | 23 (34) | – | |
| Insulin (%) | 34 (51) | – | |
| Other treatment | |||
| Statin (%) | 30 (45) | 5 (36) | 0.38 |
| ACE inhibitor/ARB (%) | 34 (51) | 5 (36) | 0.23 |
| CCB (%) | 23 (34) | 7 (50) | 0.21 |
Data are presented as number (%) or mean ± SD.
BMI body mass index, SBP/DBP systolic/diastolic blood pressure, HR heart rate, RPP rate pressure product, ACE inhibitor/ARB angiotensin-converting enzyme inhibitor/angiotensin-receptor blocker, CCB calcium channel blocker.
Laboratory and echocardiographic data
| Variables | Patients n = 67 | Controls n = 14 | p |
|---|---|---|---|
| Laboratory data | |||
| FBS (mg/dl) | 130.9 ± 40.1 | 97.0 ± 6.7 | <0.0001 |
| HbA1c (%) | 7.8 ± 1.5 | 5.2 ± 0.2 | <0.0001 |
| IRI (µU/l) | 8.8 ± 8.3 | – | |
| HOMA-R | 2.9 ± 3.2 | – | |
| TG (mg/dl) | 112.7 ± 50.2 | 120.0 ± 48.1 | 0.64 |
| HDL-C (mg/dl) | 46.1 ± 14.0 | 48.3 ± 7.7 | 0.43 |
| LDL-C (mg/dl) | 107.5 ± 27.2 | 114.0 ± 31.9 | 0.50 |
| Creatinine (mg/dl) | 0.79 ± 0.19 | 0.74 ± 0.14 | 0.31 |
| eGFR ml/min./1.73 m2 | 78.1 ± 19.3 | 79.9 ± 13.3 | 0.69 |
| Echocardiographic data | |||
| Left atrial diameter (mm) | 36.2 ± 4.4 | 33.5 ± 4.3 | 0.044 |
| RWT | 0.43 ± 0.07 | 0.43 ± 0.06 | 0.72 |
| LV mass index (g/m2) | 84.7 ± 21.4 | 77.1 ± 14.7 | 0.13 |
| LVEDV index (ml/m2) | 55.8 ± 11.4 | 54.3 ± 8.9 | 0.61 |
| LVESV index (ml/m2) | 18.2 ± 5.0 | 18.5 ± 3.3 | 0.81 |
| LVEF (%) | 67.2 ± 5.1 | 65.6 ± 5.1 | 0.34 |
| E/A | 0.9 ± 0.3 | 0.9 ± 0.2 | 0.42 |
| DT (msec) | 194.8 ± 45.1 | 182.9 ± 42.0 | 0.37 |
| Septal e′ (cm/sec) | 7.0 ± 2.2 | 7.9 ± 1.7 | 0.11 |
| E/e′ | 9.3 ± 2.7 | 7.6 ± 1.1 | 0.0004 |
| MDV baseline (cm/sec) | 15.3 ± 3.5 | 15.2 ± 3.9 | 0.89 |
| MDV hyperemia (cm/sec) | 50.6 ± 12.6 | 56.8 ± 11.6 | 0.088 |
| CFR | 3.3 ± 0.8 | 3.8 ± 0.7 | 0.036 |
Data are presented as mean ± SD.
FBS fasting blood sugar, HbA1c glycated hemoglobin, IRI immunoreactive insulin, HOMA-R homeostasis model assessment ratio, T-Cho total-cholesterol, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, eGFR estimated glomerular filtration rate, RWT relative wall thickness, LVEDV/ESV left ventricular end-diastolic volume/end-systolic volume, LVEF left ventricular ejection fraction, DT deceleration time of mitral E wave, MDV mean diastolic coronary flow velocity, CFR coronary flow reserve.
Fig. 3Distribution of diastolic dysfunction in age-matched controls and patients with type 2 diabetes.
Univariate and multivariate analysis of the variables associated with E/e′ (n = 67)
| Variables | Univariate | Multivariate | ||
|---|---|---|---|---|
| β | p | β | p | |
| Age | 0.36 | 0.0033 | 0.22 | 0.12 |
| Female | 0.21 | 0.086 | ||
| BMI | −0.048 | 0.70 | ||
| Hypertension | 0.32 | 0.0095 | 0.13 | 0.29 |
| RPP | −0.035 | 0.78 | ||
| LVEF | 0.17 | 0.17 | ||
| LV mass index | 0.33 | 0.0076 | 0.27 | 0.023 |
| eGFR | −0.25 | 0.042 | 0.00025 | 0.99 |
| FBS | 0.11 | 0.40 | ||
| HbA1c | −0.079 | 0.53 | ||
| HOMA-R | 0.016 | 0.89 | ||
| LDL-C | 0.00056 | 0.99 | ||
| TG | 0.084 | 0.50 | ||
| CFR | −0.34 | 0.0055 | −0.24 | 0.043 |
Abbreviations as in Tables 1 and 2.
Fig. 4Inverse association between CFR and surrogate marker of LV filling pressure (E/e′) in patients with type 2 diabetes.